The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

Table 8

Review of retrospective literature on combination of RT and IFN α-2b for nonmelanoma.

Study	Site	Systemic agents	Radiation	Outcome
Maasilta et al. [11, 12]	lung cancer 𝑛=10	cisplatin and etoposide combined with IFN α-2b at 3 million units IM as well as 1.5 million units by jet inhaler nebulizer	1.25 Gy given twice/day to a total dose of 60 Gy	severe esophagitis (𝑛=4)
Hoffmann et al. [13]	lung cancer 𝑛=6	cis-retinoic acid with IFN α-2b 3 million units subcutaneous 3 times/wk	50–70 Gy over 5–7 weeks	mucositis 20–50% cases
Selman et al. [14]	lung cancer 𝑛=38	IFN α-2b 6 million units/day for 5 days before radiation therapy and 3 million units 4 days afterwards	55–60 Gy	response 10/26 in those receiving IFN α-2b with toxicity of less fibrosis and more pneumonitis
Stevens et al. [15]	lung cancer 𝑛=6	IFN 𝛼-2b 2 million units subcutaneously 3 times/week	54–66 Gy	no appreciable benefit
Verastegui et al. [16]	cervix 𝑛=18	5 million units subcutaneously 3 times/week of IFN 𝛼-2b	extracavitary and intracavitary radiation, 6–10 Gy	five year survival 28% compared to 7% in the control group; 94% of 17 patients developed proctitis requiring colostomy
Rahn et al. [17]	cervix 𝑛=4	IFN 𝛼-2b, 3 million units subcutaneously 3 times/week as well as cis-retinoic acid	various	25% Grade 3 desquamation and erythema
Antonadou et al. [18]	cervix	3 million units/day of IFN 𝛼-2b and 13-cis retinoic acid	various	“well tolerated”